Astria Therapeutics Management
Management criteria checks 3/4
Astria Therapeutics' CEO is Jill Milne, appointed in Jun 2008, has a tenure of 16.42 years. total yearly compensation is $2.96M, comprised of 20.4% salary and 79.6% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $50.40K. The average tenure of the management team and the board of directors is 4.7 years and 9.1 years respectively.
Key information
Jill Milne
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 20.4% |
| CEO tenure | 16.4yrs |
| CEO ownership | 0.008% |
| Management average tenure | 4.7yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11
Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
Feb 04We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Dr. Chris Morabito is the new medical chief of Astria Therapeutics
Jul 15Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Jun 30Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital
Jun 15Catabasis Pharma shares surge after Quellis Biosciences deal
Jan 29Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?
Dec 10
Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$93m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$3m | US$602k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$2m | US$568k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$65m |
| Dec 31 2021 | US$3m | US$536k | -US$219m |
| Sep 30 2021 | n/a | n/a | -US$219m |
| Jun 30 2021 | n/a | n/a | -US$222m |
| Mar 31 2021 | n/a | n/a | -US$199m |
| Dec 31 2020 | US$1m | US$520k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$1m | US$501k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$24m |
| Dec 31 2018 | US$1m | US$476k | -US$26m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$633k | US$462k | -US$27m |
Compensation vs Market: Jill's total compensation ($USD2.96M) is about average for companies of similar size in the US market ($USD3.23M).
Compensation vs Earnings: Jill's compensation has increased whilst the company is unprofitable.
CEO
Jill Milne (56 yo)
16.4yrs
Tenure
US$2,955,504
Compensation
Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 16.4yrs | US$2.96m | 0.0078% $ 50.4k | |
| CFO & Treasurer | 4.9yrs | US$1.35m | 0% $ 0 | |
| Chief Medical Officer | 2.3yrs | US$1.32m | 0% $ 0 | |
| Chief Legal Officer | 4.4yrs | US$845.83k | 0% $ 0 | |
| Senior Vice President of Human Resources | 3.6yrs | no data | no data | |
| Chief Business Officer | 7.2yrs | no data | no data | |
| Chief Commercial Officer | 5.2yrs | no data | no data | |
| Senior Vice President of Pharmaceutical Sciences & Technical Operations | 1.3yrs | no data | no data |
4.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: ATXS's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 16.4yrs | US$2.96m | 0.0078% $ 50.4k | |
| Independent Director | 8.6yrs | US$157.67k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 10.8yrs | US$194.17k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.8yrs | US$163.67k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 9.1yrs | US$589.63k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
9.1yrs
Average Tenure
70yo
Average Age
Experienced Board: ATXS's board of directors are considered experienced (9.1 years average tenure).